Teleflex Inc key statistics and ratios
In fiscal 2025, Teleflex Inc had return on equity of -24.5%, an operating margin of 5.9%, debt equal to 84.8% of equity and a current ratio of 2.54. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.
Financial ratios
| Fiscal year | 2009Dec 2009 | 2010Dec 2010 | 2011Dec 2011 | 2012Dec 2012 | 2013Dec 2013 | 2014Dec 2014 | 2015Dec 2015 | 2016Dec 2016 | 2017Dec 2017 | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | 47.8% | 48.6% | 47.5% | 48.2% | 49.5% | 51.2% | 52.2% | 53.3% | 54.6% | 53.2% | 54.3% | 52.2% | 55.2% | 54.9% | 60.7% | 61.0% | 56.2% | 54.9% |
| Operating margin | 17.4% | 16.5% | 15.4% | −6.3% | 13.8% | 15.5% | 17.5% | 17.1% | 17.3% | 13.1% | 16.5% | 16.7% | 22.4% | 17.9% | 15.1% | 6.1% | 5.9% | 2.0% |
| Net margin | 21.1% | 14.4% | 21.7% | −12.3% | 8.9% | 10.2% | 13.5% | 12.7% | 7.1% | 8.2% | 17.8% | 13.2% | 17.3% | 13.0% | 20.8% | 4.1% | −45.4% | −45.8% |
| Free-cash-flow margin | 6.5% | 8.2% | 3.3% | 8.3% | 9.9% | 12.1% | 13.4% | 19.1% | 16.6% | 14.5% | 12.9% | 13.7% | 20.7% | 9.4% | 9.3% | 12.4% | 0.1% | 7.5% |
| Return on equity | 19.2% | 12.0% | 17.2% | −10.1% | 8.2% | 9.8% | 12.5% | 11.4% | 6.7% | 8.1% | 16.7% | 10.6% | 13.7% | 9.3% | 8.4% | 1.6% | −24.5% | −34.2% |
| Return on assets | 7.9% | 5.4% | 8.5% | −5.0% | 3.8% | 4.6% | 6.3% | 6.1% | 3.0% | 3.2% | 7.3% | 5.0% | 6.9% | 5.3% | 4.9% | 1.0% | −12.9% | −15.0% |
| Asset turnover | 0.37 | 0.37 | 0.39 | 0.41 | 0.43 | 0.45 | 0.46 | 0.48 | 0.43 | 0.39 | 0.41 | 0.38 | 0.40 | 0.40 | 0.24 | 0.23 | 0.28 | 0.33 |
| Current ratio | 2.98 | 2.19 | 4.72 | 3.90 | 1.89 | 1.57 | 1.51 | 2.77 | 2.33 | 2.12 | 2.32 | 2.63 | 2.10 | 2.43 | 2.32 | 2.27 | 2.54 | 2.60 |
| Debt to equity | 75.7% | 69.4% | 65.1% | 57.6% | 85.8% | 75.2% | 73.6% | 48.9% | 93.4% | 85.7% | 64.5% | 74.9% | 49.6% | 42.8% | 41.1% | 38.9% | 84.8% | 97.3% |
| Interest cover (operating income ÷ interest) | 2.8x | 2.9x | 3.3x | n/m | 4.1x | 4.4x | 5.2x | 5.8x | 4.5x | 3.1x | 5.3x | 6.4x | 11.0x | 9.2x | 3.0x | 1.2x | 1.2x | 0.4x |
| Effective tax rate | 22.6% | 16.2% | 17.8% | — | 13.4% | 13.0% | 3.2% | 3.3% | 45.5% | 10.6% | −35.9% | 6.1% | 13.3% | 18.6% | 22.6% | — | — | — |
| R&D as % of revenue | 2.6% | 3.0% | 3.3% | 3.6% | 3.8% | 3.3% | 2.9% | 3.1% | 3.9% | 4.3% | 4.4% | 4.7% | 4.7% | 5.5% | 6.6% | 6.4% | 7.3% | 7.1% |
| SG&A as % of revenue | 27.1% | 28.9% | 28.4% | 29.3% | 29.6% | 31.5% | 31.4% | 30.2% | 32.6% | 32.6% | 32.8% | 29.3% | 30.6% | 30.9% | 36.4% | 39.7% | 36.1% | 32.0% |
| Capital spending as % of revenue | 1.8% | 2.1% | 3.0% | 4.2% | 3.7% | 3.7% | 3.4% | 2.8% | 3.3% | 3.3% | 4.0% | 3.6% | 2.5% | 2.8% | 2.7% | 5.3% | 4.8% | 3.4% |
| Free cash flow ÷ net income | 30.9% | 56.9% | 15.4% | — | 111.2% | 118.6% | 98.8% | 150.6% | 233.0% | 176.4% | 72.5% | 103.3% | 119.6% | 72.6% | 44.8% | 303.5% | — | — |
| Dividends ÷ net income | 17.8% | 27.0% | 17.1% | — | 37.1% | 30.0% | 23.1% | 24.8% | 40.1% | 31.0% | 13.6% | 18.9% | 13.1% | 17.6% | 17.9% | 91.2% | — | — |
| Dividends and buybacks ÷ free cash flow | 57.6% | 47.4% | 110.8% | 43.0% | 33.3% | 25.3% | 23.4% | 16.5% | 17.2% | 17.5% | 18.8% | 18.2% | 11.0% | 24.2% | 40.0% | 124.6% | >999% | 184.0% |
| Quarter | 2024 Q3Sept 2024 | 2024 Q4Dec 2024 | 2025 Q1Mar 2025 | 2025 Q2Jun 2025 | 2025 Q3Sept 2025 | 2025 Q4Dec 2025 | 2026 Q1Mar 2026 | 2026 Q2Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Gross margin | 61.1% | 60.8% | 61.7% | 60.1% | 51.5% | 54.0% | 56.1% | 58.2% |
| Operating margin | 16.9% | 11.9% | 18.3% | 20.6% | −11.0% | 2.4% | 3.7% | 12.8% |
| Net margin | 26.0% | −30.9% | 22.9% | 27.7% | −72.1% | −125.5% | −1.5% | 17.5% |
| Free-cash-flow margin | 49.3% | −29.4% | 0.9% | −14.6% | 27.4% | −16.3% | 5.1% | 13.7% |
| Current ratio | 2.42 | 2.27 | 2.28 | 2.41 | 2.57 | 2.54 | 2.55 | 2.60 |
| Debt to equity | 39.2% | 38.7% | 46.6% | 44.8% | 69.9% | 84.5% | 84.9% | 96.7% |
| R&D as % of revenue | 9.1% | −1.8% | 6.1% | 6.0% | 10.1% | 2.2% | 8.1% | 7.9% |
| SG&A as % of revenue | 58.0% | −15.0% | 36.9% | 31.1% | 49.7% | 0.1% | 41.2% | 37.4% |
Financial health
- Short-term assets cover short-term liabilities $1.9bn of assets due within a year against $720m of liabilities due within a year.
- Short-term assets cover long-term liabilities $1.9bn short-term assets against $3.2bn of longer-dated liabilities.
- More cash than debt $300m of cash against $2.8bn of debt.
- Debt below 40% of shareholders' equity Debt is 97% of equity.
- Debt burden no higher than five years ago Debt to equity moved from 46% to 97% over five years.
- A year's operating cash flow covers at least 20% of debt $245m of operating cash flow against $2.8bn of debt.
- Operating profit covers interest at least five times over Operating income of $44m against $114m of interest.
Moat
Moderate moat
How hard Teleflex's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.
- Returns on capital 9 / 20
Cash operating profit has been a median 7.9% of total assets over 10 years.
- Pricing power 16 / 20
Gross margin has been a median 55.0%, moving by 4.5 percentage points (standard deviation) across 10 years.
- Durability 5 / 20
Operating margin has been a median 16.6%; its worst year was -1.9%.
- Cash conversion 17 / 20
Free cash flow was positive in 10 of 10 years, at a median 13.8% of revenue.
- Discipline 19 / 20
The diluted share count fell 6.8% over five years; stock-based pay has been a median 0.9% of revenue.
AI disruption exposure: Low. In this industry, the business rests on physical assets, regulated networks or products AI itself depends on.
Compare with peers
- Enovis Corp statistics
- Quidelortho Corp statistics
- Integer Holdings Corp statistics
- Revvity statistics
- Insulet Corporation statistics
Head to head: ENOV vs TFXQDEL vs TFXITGR vs TFX
More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies